Inhoud
1
2
2.1
2.2
2.3
2.4
Betekenis van de tips................................................................................................................. 19
2.5
Korte beschrijving ...................................................................................................................... 19
2.6
2.6.1
Beoogd gebruik ............................................................................................................................ 19
2.6.2
Medische indicatie ........................................................................................................................ 20
2.6.3
Beoogde patiëntengroep .............................................................................................................. 20
2.6.4
2.6.5
2.6.5.1
2.6.5.2
2.7
Bijwerkingen ............................................................................................................................... 22
2.7.1
2.7.2
2.8
Contra-indicaties ........................................................................................................................ 26
2.8.1
2.8.2
Relatieve contra-indicaties ........................................................................................................... 27
2.9
2.10
2.10.1
Gebruikersgroep........................................................................................................................... 29
2.11
2.12
2.13
2.14
2.15
2.16
Waarschuwingen ........................................................................................................................ 32
2.16.1
2.16.2
2.17
SVHC (REACH) ........................................................................................................................... 34
2.18
Adressen ..................................................................................................................................... 35
Fresenius Medical Care multiFiltratePRO IFU-NL 14A-2022
.................................................................................................................... 13
................................................................................................................ 17
Prestatiekenmerken ................................................................................................. 21
Klinische voordelen .................................................................................................. 21
3